if subject be currently receive a tricyclic antidepressant anticonvulsant and/or class i antiarrhythmic e.g. amitriptyline mexiletine phenytoin gabapentin or carbamazepine for treatment of pain or any other condition subject must be willing and able to maintain stable dos of these agent within 4 week prior to randomization and throughout the study i.e. dos can not be increase or decrease during this period 